Effects of N-acetylcysteine on Muscle Fatigue in Hemodialysis

Muscle dysfunction is a major problem for patients with end-stage renal disease (ESRD). Specifically, these patients experience approximately three-fold greater muscle fatigue of the lower extremities during intermittent submaximal contractions than healthy control subjects. Thus, a treatment that could ameliorate muscle fatigue in this population has the potential to increase endurance during activities of daily living and improve quality of life. Dialysis patients have been shown to have high levels of various markers of oxidative stress, and oxidative stress has been associated with excessive muscle fatigue in other patient populations, but this link has not been established in the ESRD population.

Comparisons: The amount of muscle fatigue during intermittent submaximal quadriceps exercise between dialysis patients and controls will be compared. In addition, the degree of exercise-induced increase in markers of oxidative stress in muscle and in plasma will be compared between dialysis patients and controls and between dialysis patients who have received N-acetylcysteine for 6 days and those who have received placebo capsules.

Inclusion criteria

• age greater than 18 years
• undergoing hemodialysis for 3 months or more or healthy control without kidney disease

Exclusion criteria

• inability to give informed consent
• diagnosis of diabetes mellitus
• musculoskeletal contraindication to exercise
• infection requiring intravenous antibiotics within 2 months
• hospitalization within 2 months
• ingestion of antioxidant supplements within one month
• requirement for systemic anticoagulation
• estimated GFR <60 ml/min/1.73 m2 for healthy controls